ClinicalTrials.gg
CompletedNCT03314662Updated Jul 22, 2020Results posted

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

A Phase 3 interventional study of MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) and Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) in Influenza, Human, sponsored by Seqirus. Completed at 20 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Seqirus (part of CSL Limited) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,778
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies testing MF59 in Influenza, Human — 3 open to participants now, 3 under way, 1 of them phase 3. MF59 · Influenza, Human.

Enrollment
6th of 22
1,778 · median 549
Started
2017
with 3 others
Phase 3
6 of 22
1 open now
Registered
17th of 22
by date
Lead sponsor
2 of 22
Seqirus

Among the 22 studies testing MF59 in Influenza, Human, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 6 in phase 3, and was the 17th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 22 studies testing MF59 in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MF59

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing MF59 in Influenza, Human, or all of them as a file.
02

Study summary

This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.

03

Conditions studied

  • Influenza, Human

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 65 years old who are healthy or have co-morbidities
  • Individuals who or whose legal representative(s) have voluntarily given written consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
  • Ability to attend all scheduled visits and to comply with study procedures including diary card completion and follow-up

Exclusion criteria

Exclusion Criteria:

  • History of behavioral or cognitive impairment or psychiatric condition
  • , including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study
  • Abnormal function of the immune system
  • Receipt of any influenza vaccine within 6 months prior to enrollment in this study, or plan to receive influenza vaccine prior to the Day 22 blood collection
  • Any other clinical condition that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study

Additional eligibility criteria may be discussed by contacting the site.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,778 participants (actual)

Study arms

  • Experimental
    aQIV

    MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.

    Biological: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)

  • Experimental
    aTIV-1

    Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.

    Biological: Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)

  • Experimental
    aTIV-2

    MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.

    Biological: MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.

    The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.

    Time frame: Day 22

  2. Immunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis

    The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer \< 1:10 and a post-vaccination HI titer \>= 1:40 or a pre-vaccination HI titer \>= 1:10 and a \>= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.

    Time frame: Day 22

  3. Immunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.

    The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer \<1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.

    Time frame: Day 22

  4. Immunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.

    The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.

    Time frame: Day 22

Secondary outcomes

  1. Immunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains

    For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.

    Time frame: Day 1 and Day 22

  2. Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains

    The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.

    Time frame: Day 22/Day 1

  3. Immunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains

    The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.

    Time frame: Day 1 and Day 22

  4. Immunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains

    The SCR was defined as the percentage of subjects with either a prevaccination HI titer \<1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.

    Time frame: Day 22

  5. Safety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination

    Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.

    Time frame: Day 1 through Day 7

  6. Safety Endpoint: Number of Subjects With Unsolicited AEs

    Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.

    Time frame: Day 1 through Day 22

  7. Safety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)

    Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.

    Time frame: Day 1 through Day 181

07

Results

Posted Jul 22, 2020

Participant flow

20 study centers in the United States

Participant flow — Overall Study
MilestoneaQIVaTIV-1aTIV-2
Started889445444
Treated888444444
Completed881440439
Not completed855
Withdrew: Withdrawal by subject111
Withdrew: Lost to follow-up544
Withdrew: Death200

Outcome measures

PrimaryImmunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.

The GMT of the post-vaccination (Day 22) hemagglutination inhibition (HI) titer. The GMT ratio was defined as the GMT for aTIV-1 (or aTIV-2) over the GMT for aQIV for all of the four strains.

Time frame:
Day 22
Reported as:
Geometric mean · Geometric mean titer
Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.
Geometric mean titeraQIVaTIV-1aTIV-2aTIV-1/aTIV-2
A/H1N165.01 (57.79 to 73.13)NA (NA to NA)NA (NA to NA)75.16 (66.68 to 84.72)
A/H3N2294.91 (261.88 to 332.09)NA (NA to NA)NA (NA to NA)293.31 (259.91 to 330.99)
B/Yamagata24.67 (22.67 to 26.84)15.96 (14.48 to 17.59)24.30 (22.00 to 26.84)NA (NA to NA)
B/Victoria30.78 (28.27 to 33.51)30.13 (27.31 to 33.24)21.80 (19.73 to 24.09)NA (NA to NA)
Statistical analysis
  • aQIV vs aTIV-1 vs aTIV-2 · Gmt ratio (ativ/aqiv): 1.16 · 95% CI 1.05 to 1.27GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log10 transformed), age, sex, vaccination history, study site
  • aQIV vs aTIV-1 vs aTIV-2 · Gmt ratio: (ativ/aqiv: 0.99 · 95% CI 0.90 to 1.09GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log 10 transformed), age, sex, vaccination history, study site
  • aQIV vs aTIV-1 vs aTIV-2 · Gmt ratio: ativ/aqiv: 0.99 · 95% CI 0.90 to 1.08GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log10 transformed), age, sex, vaccination history, study site
  • aQIV vs aTIV-1 vs aTIV-2 · Gmt ratio: (ativ/aqiv)]: 0.98 · 95% CI 0.89 to 1.08GMT ratios (adjusted) obtained from a GLM fitted on log-transformed (base 10) post-vaccination HI titer as outcome variable and covariate terms: treatment, pre-vaccination HI titer (log10 transformed), age, sex, vaccination history, study site
PrimaryImmunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis

The SCR is defined as the percentage of subjects with either a pre-vaccination HI titer \< 1:10 and a post-vaccination HI titer \>= 1:40 or a pre-vaccination HI titer \>= 1:10 and a \>= 4-fold increase in post-vaccination HI titer. The SCR Difference is defined as the difference between the SCR of post- vaccination (Day 22) HI titer for aTIV-1 (or aTIV-2) and the SCR of post-vaccination (Day 22) HI titer for aQIV. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.

Time frame:
Day 22
Reported as:
Number · percentage of subjects
Immunogenicity Endpoint: The Difference Between the Seroconversion Rate (SCR) for the Four Strains Included in the Vaccine, Non-inferiority Analysis
percentage of subjectsaQIVaTIV-1aTIV-2
A/H1N135.21 (32 to 38.5)39.45 (34.8 to 44.2)37.41 (32.8 to 44.2)
A/H3N239.33 (36.1 to 42.7)39.70 (36.4 to 43.0)37.18 (32.6 to 41.9)
B/Yamagata16.4 (14.0 to 19.0)NA (NA to NA)15.47 (12.2 to 19.2)
B/Victoria13.42 (11.2 to 15.9)12.16 (9.24 to 15.6)NA (NA to NA)
Statistical analysis
  • aQIV vs aTIV-1 vs aTIV-2 · Scr difference (ativ minus aqiv): 3.23 · 95% CI -1.30 to 7.76
  • aQIV vs aTIV-1 vs aTIV-2 · Scr difference (ativ minus aqiv): 0.37 · 95% CI -4.23 to 4.96
  • aQIV vs aTIV-1 vs aTIV-2 · Scr difference (ativ minus aqiv)]: -0.93 · 95% CI -5.13 to 3.27
  • aQIV vs aTIV-1 vs aTIV-2 · Other [scr difference (ativ minus aqiv)]: -1.26 · 95% CI -5.07 to 2.55
PrimaryImmunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.

The percentage of subjects vaccinated with aQIV achieving SCR at Day 22 was assessed for each of the 4 strains. SCR was defined as the percentage of subjects with either a pre-vaccination HI titer \<1:10 and a post-vaccination HI titer ≥1:40 or a pre-vaccination HI titer ≥1:10 and a ≥4-fold increase in post-vaccination HI titer. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving SCR for HI antibody should meet or exceed 30%.

Time frame:
Day 22
Reported as:
Number · Percentage of subjects
Immunogenicity Endpoint: The Percentage of Subjects Achieving SCR for Hemagglutination Inhibition (HI) Antibody for the Four Strains Included in the Vaccine.
Percentage of subjectsaQIVaTIV-1aTIV-2
A/H1N135.21 (32.03 to 38.48)39.45 (34.80 to 44.20)37.41 (32.8 to 40.20)
A/H3N239.33 (36.08 to 42.67)39.70 (36.43 to 43.04)37.18 (32.6 to 41.9)
B/Yamagata16.40 (14.0 to 19.03)NA (NA to NA)15.47 (12.2 to 19.2)
B/Victoria13.42 (11.22 to 15.86)12.16 (9.24 to 15.60)NA (NA to NA)
PrimaryImmunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.

The percentage of subjects vaccinated with aQIV achieving HI antibody titers ≥ 1:40 at Day 22 was assessed for each of the 4 strains. Assessment criteria was considered fulfilled if the lower bound of the two-sided 95% confidence interval for the percentage of subjects achieving a post-vaccination HI antibody titer ≥ 1:40 should meet or exceed 60%.

Time frame:
Day 22
Reported as:
Number · Percentage of subjects
Immunogenicity Endpoint: The Percent of Subjects Achieving an HI Antibody Titer ≥ 1:40 for the Four Strains Included in the Vaccines.
Percentage of subjectsaQIVaTIV-1aTIV-2
A/H1N169.38 (66.20 to 72.43)71.79 (67.31 to 75.97)68.82 (64.23 to 73.16)
A/H3N293.92 (92.12 to 95.41)94.72 (92.19 to 96.63)94.92 (92.41 to 96.79)
B/Yamagata32.80 (29.69 to 36.03)21.79 (18.00 to 25.96)36.95 (32.39 to 41.69)
B/Victoria38.19 (34.95 to 41.51)36.93 (32.38 to 41.65)24.48 (20.50 to 28.81)
SecondaryImmunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains

For the assessment of GMTs using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the GMT ratio (aTIV/aQIV) at Day 22.

Time frame:
Day 1 and Day 22
Reported as:
Geometric mean · geometric mean titer
Immunogenicity Endpoint: Geometric Mean Titers (GMT) Against Homologous Strains
geometric mean titeraQIVaTIV-1aTIV-2aTIV-1/aTIV-2
A/H1N1 Day 119.07 (17.66 to 20.60)NA (NA to NA)NA (NA to NA)18.77 (17.47 to 20.17)
A/H1N1 Day 2257.07 (52.67 to 61.84)NA (NA to NA)NA (NA to NA)63.73 (58.60 to 69.32)
A/H3N2 Day 173.27 (66.36 to 80.90)NA (NA to NA)NA (NA to NA)71.83 (65.39 to 78.90)
A/H3N2 Day 22245.85 (225.57 to 267.95)NA (NA to NA)NA (NA to NA)236.27 (217.53 to 256.63)
B/Yamagata Day 110.41 (9.86 to 10.98)NA (NA to NA)10.76 (9.97 to 11.61)NA (NA to NA)
B/Yamagata Day 2221.15 (19.75 to 22.66)NA (NA to NA)20.74 (18.86 to 22.80)NA (NA to NA)
B/Victoria Day 114.15 (13.30 to 15.05)15.18 (13.85 to 16.64)NA (NA to NA)NA (NA to NA)
B/Victoria Day 2224.91 (23.21 to 26.74)25.54 (23.03 to 28.33)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • aQIV vs aTIV-1 · Gmt ratio: 0.64 · 95% CI 0.58 to 0.70
  • aQIV vs aTIV-2 · Gmt ratio: 0.71 · 95% CI 0.64 to 0.78
SecondaryImmunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains

The GMR was assessed as the postvaccination HI titer divided by the prevaccination HI titer (Day 22/Day 1). aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2.

Time frame:
Day 22/Day 1
Reported as:
Geometric mean · geometric mean ratio
Immunogenicity Endpoint: Geometric Mean Ratio (GMR) of Post Vaccination HI Titer Over the Pre-vaccination HI Titer Against Homologous Strains
geometric mean ratioaQIVaTIV-1aTIV-2aTIV-1/aTIV-2
A/H1N12.99 (2.78 to 3.22)NA (NA to NA)NA (NA to NA)3.40 (3.14 to 3.67)
A/H3N23.36 (3.07 to 3.66)NA (NA to NA)NA (NA to NA)3.29 (3.02 to 3.59)
B/Yamagata2.03 (1.92 to 2.15)NA (NA to NA)1.93 (1.79 to 2.08)NA (NA to NA)
B/Victoria1.76 (1.66 to 1.86)1.68 (1.55 to 1.82)NA (NA to NA)NA (NA to NA)
SecondaryImmunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains

The percentage of subjects with HI titer of ≥1:40 at Day 1 (prevaccination) and Day 22 (postvaccination) was assessed for homologous strains. aTIV-1 and aTIV-2 vaccine groups are pooled for the analysis of A-H1N1 and A-H3N2 strains. For B/Victoria TIV=TIV-1. For B/Yamagata TIV=TIV-2.

Time frame:
Day 1 and Day 22
Reported as:
Number · percentage of subjects
Immunogenicity Endpoint: The Percentage of Subjects With a Titer ≥1:40 Against Homologous Strains
percentage of subjectsaQIVaTIV-1aTIV-2aTIV-1/aTIV-2
A/H1N1 Day 133.26 (30.13 to 36.49)NA (NA to NA)NA (NA to NA)31.07 (28.00 to 34.27)
A/H1N1 Day 2269.38 (66.20 to 72.43)NA (NA to NA)NA (NA to NA)70.31 (67.15 to 73.33)
A/H3N2 Day 170.64 (67.50 to 73.65)NA (NA to NA)NA (NA to NA)70.66 (67.50 to 73.67)
A/H3N2 Day 2293.92 (92.12 to 95.41)NA (NA to NA)NA (NA to NA)94.82 (93.13 to 96.20)
B/Yamagata Day 111.12 (9.11 to 13.40)NA (NA to NA)11.55 (8.69 to 14.94)NA (NA to NA)
B/Yamagata Day 2232.80 (26.69 to 36.03)NA (NA to NA)36.95 (32.39 to 41.69)NA (NA to NA)
B/Victoria Day 119.72 (17.13 to 22.52)22.71 (18.86 to 26.93)NA (NA to NA)NA (NA to NA)
B/Victoria Day 2238.19 (34.95 to 41.51)36.93 (32.38 to 41.65)NA (NA to NA)NA (NA to NA)
SecondaryImmunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains

The SCR was defined as the percentage of subjects with either a prevaccination HI titer \<1:10 and a postvaccination HI titer ≥1:40 or a prevaccination HI titer ≥1:10 and a ≥4-fold increase in postvaccination HI titer. For assessment if SCR using HI assay, aTIV-1 and aTIV-2 vaccine groups were pooled for the analysis of A-H1N1 and A-H3N2 strains. For B-Victoria TIV=aTIV-1. For B-Yamagata TIV=aTIV-2. The immunologic superiority in HI antibody responses for the alternate B strain (eg, the influenza B strain included in the aQIV but not in the aTIV formulation) were assessed for each aTIV separately, using the difference in SCR (aTIV-aQIV) at Day 22.

Time frame:
Day 22
Reported as:
Number · Percentage of subjects
Immunogenicity Endpoint: The Percentage of Subjects With SCR Against Homologous Strains
Percentage of subjectsaQIVaTIV-1aTIV-2aTIV-1/aTIV-2
A/H1N135.21 (32.03 to 38.48)NA (NA to NA)NA (NA to NA)38.43 (35.19 to 41.76)
A/H3N239.33 (36.08 to 42.67)NA (NA to NA)NA (NA to NA)39.70 (36.43 to 43.04)
B/Yamagata16.40 (14.00 to 19.03)NA (NA to NA)15.47 (12.20 to 19.23)NA (NA to NA)
B/Victoria13.42 (11.22 to 15.86)12.16 (9.24 to 15.60)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • aQIV vs aTIV-1 · Scr difference: -11.96 · 95% CI -15.12 to -8.81
  • aQIV vs aTIV-2 · Scr difference: -10.82 · 95% CI -13.54 to -8.11
SecondarySafety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination

Safety of vaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.

Time frame:
Day 1 through Day 7
Reported as:
Count of participants · Participants
Safety Endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs) Following Vaccination
ParticipantsaQIVaTIV-1aTIV-2
Any local solicited AE385170167
Any systemic solicited AE231107110
SecondarySafety Endpoint: Number of Subjects With Unsolicited AEs

Safety of vaccination was assessed in terms of percentage of subjects reporting unsolicited AEs up to 21 days after vaccination.

Time frame:
Day 1 through Day 22
Reported as:
Count of participants · Participants
Safety Endpoint: Number of Subjects With Unsolicited AEs
ParticipantsaQIVaTIV-1aTIV-2
Safety Endpoint: Number of Subjects With Unsolicited AEs1365068
SecondarySafety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)

Safety of vaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, and AESIs and medically attended AE up to 180 days after vaccination.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Safety Endpoint: Number of Subjects With Serious AEs (SAEs), AEs Leading to Withdrawal From the Study, New Onset of Chronic Diseases (NOCDs) and AEs of Special Interest (AESIs)
ParticipantsaQIVaTIV-1aTIV-2
SAEs372818
AEs leading to withdrawal000
NOCDs231614
AESIs110

Adverse events

Collected over SAEs and unsolicited AEs: Day 1 through 181; Solicited AEs: Day 1 through 7. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
aQIV2/888 (0.2%)37/888 (4.2%)461/888 (51.9%)
aTIV-10/444 (0%)28/444 (6.3%)217/444 (48.9%)
aTIV-20/444 (0%)18/444 (4.1%)215/444 (48.4%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventaQIVaTIV-1aTIV-2
PneumoniaInfections and infestations7/8884/4441/444
OsteoarthritisMusculoskeletal and connective tissue disorders3/8883/4440/444
Coronary artery diseaseCardiac disorders1/8881/4442/444
InfluenzaInfections and infestations1/8880/4442/444
Carotid artery stenosisNervous system disorders1/8882/4440/444
ThrombocytopeniaBlood and lymphatic system disorders0/8881/4440/444
Atrial fibrillationCardiac disorders1/8880/4441/444
Angina pectorisCardiac disorders0/8880/4441/444
Myocardial infarctionCardiac disorders0/8881/4440/444
Sinus node dysfunctionCardiac disorders0/8881/4440/444
Most frequent other events
Most frequent other events
EventaQIVaTIV-1aTIV-2
PainGeneral disorders275/888125/444109/444
RednessGeneral disorders188/88877/44481/444
FatigueGeneral disorders144/88867/44452/444
SwellingGeneral disorders134/88869/44464/444
HeadacheNervous system disorders105/88846/44449/444
ArthralgiaMusculoskeletal and connective tissue disorders80/88837/44431/444
MyalgiaMusculoskeletal and connective tissue disorders71/88834/44431/444
EcchymosisGeneral disorders69/88828/44423/444
DiarrheaGastrointestinal disorders48/88824/44430/444
OtherGeneral disorders48/88812/44417/444

Baseline characteristics

Age, Continuous
Age, Continuous(years)aQIVaTIV-1aTIV-2Total
Mean72.4 ± 5.5472.4 ± 5.6072.6 ± 5.4672.5 ± 5.53
Sex: Female, Male
Sex: Female, Male(Participants)aQIVaTIV-1aTIV-2Total
Female5172492411007
Male372196203771
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)aQIVaTIV-1aTIV-2Total
White8144034111628
Black or African American593729125
Asian92112
Native Hawaiian or Pacific Islander1102
American Indian or Alaska Native5027
Other1214
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)aQIVaTIV-1aTIV-2Total
Hispanic or Latino593731127
Not Hispanic or Latino8274084101645
Not Reported2024
Unknown1012
Region of Enrollment
Region of Enrollment(participants)aQIVaTIV-1aTIV-2Total
United States8894454441778
Height
Height(cm)aQIVaTIV-1aTIV-2Total
Mean167.54 ± 9.350167.92 ± 10.535168.38 ± 10.646167.84 ± 9.990
Weight
Weight(kg)aQIVaTIV-1aTIV-2Total
Mean83.24 ± 19.06484.18 ± 8.96384.24 ± 17.82583.73 ± 18.731
BMI
BMI(kg/m^2)aQIVaTIV-1aTIV-2Total
Mean29.60 ± 6.15729.79 ± 5.85829.69 ± 5.64729.67 ± 5.956

2 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Paradigm clinical Research Centers, Inc
    Redding, California 96001, United States
  • Clinical Research of South Florida, an AMR Company
    Coral Gables, Florida 33134, United States
  • Meridan Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Heartland Research Associates, LLC - An AMR Company
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC - An AMR Company
    Wichita, Kansas 67207, United States
  • Center for Pharmaceutical Research, LLC
    Kansas City, Missouri 64114, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • United Medical Associates
    Binghamton, New York 13901, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Benchmark Research
    San Angelo, Texas 76904, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
09

References and documents

Publications

  • Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, Edelman J, Smolenov I. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 2020 Jan 10;38(2):242-250. doi: 10.1016/j.vaccine.2019.10.021. Epub 2019 Oct 18. PubMed 31635976 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2017, 1 month.

Results were first posted in Jul 2020, 2 years 7 months after primary completion. A results delay was requested in Nov 2018.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 1 month is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2017
First posted
Oct 19, 2017
StartActual
Oct 17, 2017
Primary completionActual
Dec 11, 2017
CompletionActual
May 17, 2018
Results delay requested
Nov 21, 2018
Results first posted
Jul 22, 2020
Last update
Jul 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03314662
Lead sponsor
Seqirus
Responsible party
Sponsor
First posted
Oct 19, 2017
Start date
Oct 17, 2017
Primary completion
Dec 11, 2017
Completion
May 17, 2018
Results posted
Jul 22, 2020
Last update
Jul 22, 2020

Study contacts

Clinical Scientist
study director · Seqirus

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MF59

Start the discussion